Newsroom

Sorted by: Latest

-

Mantis Innovation Launches Next‑Generation Perform Platform to Elevate Facility and Energy Decision‑Making

HOUSTON--(BUSINESS WIRE)--Mantis Innovation, a national facility performance and energy efficiency consulting firm, today announced the launch of its next‑generation Perform platform, advancing how organizations understand, prioritize, and act on facility and energy data across their portfolios. As facility and energy teams manage increasingly complex operations, many struggle with fragmented data, disconnected reporting, and limited visibility into how asset conditions, energy performance, cap...
-

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX)(“Aditxt” or the “Company”), a life sciences platform company accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision oncology diagnostics subsidiary Ignite Proteomics, LLC (“Ignite”) since March 2026, will now lead the full Ad...
-

BeOne Medicines établit une nouvelle référence en matière de contrôle à long terme de la LLC grâce aux données sur 78 mois concernant BRUKINSA présentées lors de l’ASCO 2026

SAN CARLOS, Californie--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq : ONC ; HKEX : 06160 ; SSE : 688235), une société mondiale spécialisée en oncologie, fait évoluer le paradigme thérapeutique de la leucémie lymphoïde chronique (LLC) lors du congrès annuel 2026 de l’American Society of Clinical Oncology (ASCO). Grâce à un suivi à long terme approfondi, l’étude SEQUOIA sur BRUKINSA® (zanubrutinib) renforce son rôle d’inhibiteur de BTK de référence, démontrant un contrôle durable de la maladie...
-

GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations

CHICAGO--(BUSINESS WIRE)--As theranostics adoption acceleratesi and radiopharmaceutical demand grows,ii healthcare systems are under increasing pressure to scale nuclear medicine operations while improving diagnostic confidence and workflow efficiency. At the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare showcases its latest technologies and AI-enabled workflows to help support precision care across care pathways. Nuclear medicine is undergoing rap...
-

Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics Presents Updated Results from Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at ASCO Annual Meeting...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx NextG UCITS ETF 29.05.2026 NXTG.LN IE00BWTNM743 170,002.00 USD 9,900,303.52 58.236  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones International Internet UCITS ETF 29.05.2026 FDNI.LN IE00BT9PVG14 450,002.00 USD 8,173,856.67 18.164  ...
-

SmartBear Advances TestComplete with Vision AI, Enabling Automated Testing for Highly Critical Visual Applications

SOMERVILLE, Mass.--(BUSINESS WIRE)--SmartBear, helping teams build, test, and ship quality software at AI speed and scale, today announced the first platform to unify property-based, OCR, and vision AI — expanding coverage, reducing risk, and perceiving applications the way humans do. This functionality will automate testing of highly visual applications that are traditionally tested manually because of their complexity, leading to poorer coverage and increased risk exposure. Automating testing...
-

Barings BDC, Inc. Announces Early Termination of Sierra Credit Support Agreement and $67.0 Million Payment From Barings LLC

CHARLOTTE, N.C.--(BUSINESS WIRE)--Barings BDC, Inc. (NYSE: BBDC) (“Barings BDC” or the “Company”) today announced the early termination of its existing credit support agreement (“original CSA”) associated with the Company’s acquisition of Sierra Income Corporation (“Sierra”), and the implementation of a new credit support agreement covering the remaining investments in two Sierra legacy portfolio companies. The original CSA, entered into on February 25, 2022 in connection with the Sierra merger...
-

PrEP Wisdom: ViiV Healthcare Launches New Campaign to Support Informed HIV Prevention Choices

DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the launch of its PrEP Wisdom campaign, designed to empower people to make informed decisions about long-acting injectable (LAI) HIV prevention, beyond the dosing schedules. The campaign features TV personality Michelle Visage, a long-time HIV and LGBTQ advocate. Approximately 2.2 million people in the US could benefit from pre-exposure prophyl...